Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has entered into collaboration with UK-based Orca Pharmaceuticals to develop drugs to treat a wide range of autoimmune diseases such as inflammatory bowel disease, psoriasis, arthritis and multiple sclerosis.
Subscribe to our email newsletter
The three-year deal will see both companies jointly develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (ROR?).
According to AstraZeneca, RORy helps to convert a population of immune cells (CD4+ T cells) into T-helper 17 cells which produce cytokines that drive the immune response.
As part of the deal, Orca will receive an upfront payment and further fees from AstraZeneca with a potential total value of $122.5m.
AstraZeneca will gain access to Orca Pharmaceuticals-developed ROR? inhibitors and also has the option to acquire the Orca compounds at the end of the collaboration.
Orca Pharmaceuticals CEO and co-founder Dr Michael Hunter said: "We are delighted that AstraZeneca has recognized the potential of the Orca program in a space where the identification of inhibitors with drug-like properties has proven challenging.
"To have the backing and experience of AstraZeneca makes this program even more competitive as we move forward to deliver best-in-class medicines in this area," Hunter said.
Orca’s technology is focused on ROR? nuclear hormone receptor targets and its lead therapeutic program is in psoriasis.
Image: AstraZeneca headquarters in London, UK. Photo: courtesy of AstraZeneca plc.